-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|August 5, 2024

Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response

Key opinion leaders explore molecular characteristics beyond mutations that influence immunotherapy response in non small cell lung cancer treatment.

Episodes in this series

EP. 1 Biomarker Testing and Guideline-Recommended Care in mNSCLC

EP. 1 Biomarker Testing and Guideline-Recommended Care in mNSCLC

EP. 2 Strategies to Increase Biomarker Testing Rates

EP. 2 Strategies to Increase Biomarker Testing Rates

EP. 3 Limitations on Optimal Biomarker Testing Rates

EP. 3 Limitations on Optimal Biomarker Testing Rates

EP. 4 Impact of Biomarker Testing on Treatment Selection and Outcomes

EP. 4 Impact of Biomarker Testing on Treatment Selection and Outcomes

EP. 5 Key Challenges and Unmet Needs in Newly Diagnosed Driver-Negative mNSCLC

EP. 5 Key Challenges and Unmet Needs in Newly Diagnosed Driver-Negative mNSCLC

EP. 6 NCCN Recommendations by PD-L1 Expression Level

EP. 6 NCCN Recommendations by PD-L1 Expression Level

EP. 7 Limitations of NCCN PD-L1 Expression Recommendations

EP. 7 Limitations of NCCN PD-L1 Expression Recommendations

EP. 8 Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC

EP. 8 Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC

EP. 9 Genetic Alterations Impacting Treatment Response and Biomarker Testing Rates in mNSCLC

EP. 9 Genetic Alterations Impacting Treatment Response and Biomarker Testing Rates in mNSCLC

EP. 10 Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response

EP. 10 Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response

A panel of 4 experts on lung cancer

EP. 11 Clinical Factors Impacting Immunotherapy Response and Optimizing Patient Selection

A panel of 4 experts on lung cancer

EP. 12 Overcoming Immunotherapy Resistance: Identifying Non-Responders and Novel Approaches

A panel of 4 experts on lung cancer

EP. 13 Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations

Video content above is prompted by the following:

Beyond genomic mutations like STK11/KEAP1/KRAS, are there other molecular characteristics that can influence immunotherapy effectiveness and should guide treatment selection?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Experts featured in this series.

The Right Fit First: How Psychiatrists Approach Initial Treatment and Patient Adherence

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 23rd 2026 | Updated: June 16th 2026

Experts featured in this series.

Formulary Frustrations: How Insurance Constraints Shape Psychiatric Treatment Decisions

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 23rd 2026 | Updated: June 16th 2026

Navigating the Human Side of Extrapulmonary Neuroendocrine Carcinoma: Patient Burden and Caregiver Support

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

June 22nd 2026

The 5-Year Horizon: Evolving Paradigms in Ischemic Stroke Management

ByMark Makhinson, PharmD, MBA,Andrew Russman, DO, FAHA, FAAN,Danison Emmerson, MD,David Z. Rose, MD

June 22nd 2026

Closing the Gap: Underrecognition and the Critical Need for Early Diagnosis in Extrapulmonary Neuroendocrine Carcinoma

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

June 22nd 2026

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

ATTR-CM Incidence, Prevalence Rose Sharply in the US

FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance

Zanubrutinib Tops Rivals in Real-World CLL Survival Study

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention